Nanocarriers for anticancer drugs--new trends in nanomedicine
Language English Country Netherlands Media print
Document type Journal Article, Research Support, Non-U.S. Gov't, Review
PubMed
23687925
DOI
10.2174/1389200211314050005
PII: CDM-EPUB-20130513-2
Knihovny.cz E-resources
- MeSH
- Drug Delivery Systems * MeSH
- Humans MeSH
- Neoplasms drug therapy MeSH
- Nanoparticles * MeSH
- Nanomedicine MeSH
- Nanotechnology MeSH
- Drug Carriers chemistry MeSH
- Antineoplastic Agents administration & dosage chemistry therapeutic use MeSH
- Drug Design MeSH
- Solubility MeSH
- Animals MeSH
- Check Tag
- Humans MeSH
- Animals MeSH
- Publication type
- Journal Article MeSH
- Research Support, Non-U.S. Gov't MeSH
- Review MeSH
- Names of Substances
- Drug Carriers MeSH
- Antineoplastic Agents MeSH
This review provides a brief overview of the variety of carriers employed for targeted drug delivery used in cancer therapy and summarizes advantages and disadvantages of each approach. Particularly, the attention was paid to polymeric nanocarriers, liposomes, micelles, polyethylene glycol, poly(lactic-co-glycolic acid), dendrimers, gold and magnetic nanoparticles, quantum dots, silica nanoparticles, and carbon nanotubes. Further, this paper briefly focuses on several anticancer agents (paclitaxel, docetaxel, camptothecin, doxorubicin, daunorubicin, cisplatin, curcumin, and geldanamycin) and on the influence of their combination with nanoparticulate transporters to their properties such as cytotoxicity, short life time and/or solubility.
References provided by Crossref.org
